Table 1

Baseline characteristics by treatment group and study at day 0. Means are arithmetic. CQ = chloroquine, SP = sulphadoxine-pyrimethamine, AS1 = 1-dose artesunate, AS-3 = 3-dose artesunate, AL = artemether-lumefantrine (Coartem), AQ = amodiaquine.
Study &
country
 Treatment
 N
Parasitology follow
up days (bold =
transmission
experiment)
 Mean age (years)
Mean
asexual
parasite
density/μl
Mean slide-
positive
gametocyte
prevalence (%)
Mean
gametocyte
density/μl
1. Gambia Targett 2001 [22]
 CQ
 135
 4, 7,14,28
 5.9
 80,886
 2.5
 33

SP
 277
6.0
 73,742
 5.6
 13

SP-AS1
 113
6.2
 23,147
 10.7
 10

SP-AS3
 74
6.3
 26,567
 13.4
 88

all
 599
6.0
 59,581
 6.9
 26
2. Gambia Targett 2001 [22]
 SP
 101
 7,14
 4.4
 28,684
 6.0
 31

SP-AS3
 404
4.8
 27,738
 8.0
 127

all
 505
4.7
 27,927
 7.6
 107
3. Gambia Drakeley 2004 [20]
 CQ
 129
 3, 7,14,28
 4.7
 64,329
 20.2
 10

CQ-AS
 386
4.8
 66,593
 20.2
 22

all
 515
4.8
 66,026
 20.2
 19
4. Gambia Hallett 2006 [13]
 CQ
 125
 3, 7, 10, 14,28
 4.5
 63,640
 21.6
 30

SP
 180
4.5
 58,128
 23.2
 47

CQ-SP
 193
4.6
 79,900
 19.2
 37

all
 498
4.6
 68,009
 21.2
 39
5. Gambia Sutherland 2005 [21]
 CQ-SP
 89
 7,14,28
 4.3
 56,444
 4.5
 5

AL
 400
4.4
 57,550
 6.3
 9

(Coartem)






all
 489
4.3
 57,347
 6.0
 9
6. Kenya Bousema 2006 [19]
 SP
 152
 3,7, 14,28
 3.4
 19,044
 20.9
 7

SP-AQ
 127
2.9
 20,578
 22.3
 8

SP-AS3
 174
3.2
 21,620
 24.4
 8

AL (Coartem)
 75
4.0
 21,178
 24.6
 6

all
 528
3.3
 20,565
 22.9
 7

Okell et al. Malaria Journal 2008 7:125   doi:10.1186/1475-2875-7-125